Crotedumab
Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | GCGR |
Clinical data | |
Other names | REGN1193 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6518H10044N1732O2052S46 |
Molar mass | 146976.88 g·mol−1 |
This drug was developed by Regeneron Pharmaceuticals.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.